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The Background
 Nationally, over 1.2 million Americans 
currently living with HIV
 Nearly 1 in 8 (12.8%) are unaware of their 
status
 New infections consistently around 
50,000 / yr
 Men who have Sex with Men (MSM) carry 
largest burden
 25% of new infections are among youth 
(13-24yo), many whom are unaware of 
HIV status and can pass virus on to others
 Family medicine is perfectly poised to 
intervene
 In Vermont:
 Average 11-19 new Dx over past 10 
years
 Total of 670 HIV positive Vermonters 
(more accurately, closer to 800 
considering those unaware of status)
 56% of newly Dx’ed are in MSM 
population
 2016 US Federal Budget Request = $31.7 
Billion for domestic and int’l HIV efforts
 $18.5 billion = healthcare services / 
treatment for HIV+ individuals
 Only $940 million for domestic HIV 
prevention
 Unchanged for the past 6 years
The Arrival of PrEP
 2012: FDA approval of Truvada
(Emtricitabine-Tenofovir 200mg-
300mg) for Pre-Exposure 
Prophylaxis (“PrEP”)
 Drug had long history already for 
post-exposure treatment of HIV
 Clinical Practice Guidelines were 
immediately in place in cities with 
high LGBT populations (San 
Francisco City Clinic, Group Health 
Cooperative Seattle, Fenway 
Health Boston, Callen-Lorde / 
GMHC in NYC)
 Uptake / awareness elsewhere 
remains slow (especially in VT)
In Vermont
Provider comfort / familiarity remains 
limited
Latest estimate per Vermont Cares, 
excluding Planned Parenthood, UVM 
Student Health, or UVM Infectious 
Disease, is approximately [how many?] 
who have actively prescribed PrEP
In Vermont
Provider comfort / familiarity remains 
limited
Latest estimate per Vermont Cares, 
excluding Planned Parenthood, UVM 
Student Health, or UVM Infectious 
Disease, is approximately 9 providers 
who have actively prescribed PrEP


UVM COM PHP Project: Lack of Provider Training was 
the #1 Identified Barrier
College of Medicine Public Health Project Highlights
How to get the word out about 
PrEP?
 PCP and community awareness & education
 The ID community is well aware of PrEP
 2013 national survey of ID physicians demonstrated that 74% supported 
the use of PrEP, yet only 9% had actually prescribed it.
 HIV-negative, or assumed to be, gay men have no reason to see an 
ID specialist. If they’re seeing anyone for healthcare, it’s their PCP.
 Within marginalized communities, word spreads quickly about which 
providers are open and “safe” to talk to. 
Having The Talk: Approach to Clinical Assessment of 
the Patient – Sexual HIV Acquisition Risk
Sexual history taking:
- 76% of MSM surveyed in 2008 in 21 US cities reported a health care visit in the past year
- However, many providers don’t ask about (and pts don’t disclose) same-sex behaviors
- CDC suggested questions for risk assessment
- Language unique to MSM: “bottoming” vs. “topping”
*** “Are you and your partner exclusive or open?” ***
- San Francisco State Univ “Gay Couples Study”: found 47% of gay relationships are open, 45% 
monogamous, and 8% disagreed about their categorization
- focused on HIV infections rising even among primary male couples
 For all sexually active pts:
 Consider dx of bacterial STIs in past 6 months as evidence of potential 
HIV-exposure sexual activity, therefore, risk
 Alcohol use / abuse screening (especially before sexual activity)
 Screening for use of non-injection drug use in conjunction with 
sexual encounters:
 Amyl nitrite (“poppers”) – assoc’d w/ sexual encounter enhancement
 Smooth muscle (anal sphincter) relaxation, general vasodilation, and 
reflexive tachycardia (sensation of “excitement”)
 Stimulants: often popular in the circuit-party scene 
Having The Talk: Approach to Clinical Assessment of 
the Patient – Sexual HIV Acquisition Risk
CDC Clinical Provider’s Supplement
Note age 18-28
Note receptive anal sex 
without condom x1
Either of the above 
alone is nearly/ 
already at threshold 
to consider Rx of 
PrEP
Other Indications for PrEP Use
Considering the IV drug use epidemic in the state, PrEP should 
also be first and foremost in prevention of HIV infection in these 
high-risk individuals
Lab Tests and Evaluation
 1) HIV antibody test
 Confirm HIV (-) status before initiating, and every 3 months (ideally within 
the week before refilling Rx)
 Accomplish via serum HIV ELISA or rapid POC FDA approved fingerstick
blood test
 Do NOT use oral rapid tests in PrEP monitoring due to less sensitivity
 Do NOT accept self-reported results or documented anonymous results
 If positive HIV antibody: follow normal procedure for confirmatory testing
 If acute infection suspected within “window period” before antibody 
test would become positive, must defer to HIV RNA test for acute 
exposure 
Lab Tests and Evaluation
 2) Renal Function
 Obtain serum Cr and eCrCl
 Minimum eCrCl of 60ml/min
 Among HIV-infected persons prescribed Truvada-containing regimens, 
decreases in renal function (eCrCl) have been documented
 Occasional cases of acute renal failure
 3) Test for active HVB/HCV infection
 MSM and IVDU at increased risk
 Tenofovir has activity against HBV, thus if pt stops med, reactivation of 
HBV  hepatic damage
 Conduct STI testing at least every 6 months
 Importance of site-specific testing (2010 CDC STD guidelines for MSM screening)
 Urethral G/C if insertive intercourse in past year 
 Rectal G/C if receptive intercourse in past year 
 Pharyngeal G/C if receptive oral sex in past year
 Studies have not consistently borne out the idea of “risk-compensation” for 
individuals on PrEP (i.e. “PrEP instead of condoms”). Some studies have actually 
showed condom use increased long-term for individuals on PrEP
 Perhaps due to more frequent/regular STI and HIV screening for individuals on PrEP
 Anal Paps?
 NY State Dept. of Health recommends for HIV+ patients
 CDC/USPSTF/ACS do not recommend 
 Recommendations? HIV- patients = baseline, q2-3 years
Lab Tests and Evaluation
Road to Zero
 Campaign whose goal is to achieve zero new HIV infections in 
Vermont by 2020
 Average of 20 new diagnoses per year (over the past 5 years)
 “Vermont is in striking distance of becoming the first state ever to 
achieve this goal” – VT Cares
 PrEP is front and center
 Major limitation? 
 Currently only 9 providers actively prescribing PrEP
 “Insufficient to fully demonstrate the public health impact PrEP can 
have”
 Peter Jacobsen, Executive Director of VT Cares
Cost Concerns
 Truvada is covered by:
 VT Medicaid
 VT Blue Cross – Blue Shield
 Gilead “Advancing Access” Copay Card
 https://www.gileadadvancingaccess.com/copay-coupon-card 
 Covers drug cost
 U.S. residents
 Available for each valid prescription, no other purchase necessary
 Pt cannot be currently receiving other free drug assistance through Gilead 
patient assistance programs
HIV risk is not static throughout lifetime –
“seasonality” of risk
Identification of high-risk people might be less helpful than identification of 
high-risk moments and the situations that cause them, for example:
- Leaving home
- Becoming an adult
- Coming out as a MSM
- Immigrating to a new city
- Ending a relationship
** Family Medicine again is perfectly poised to intervene **
PROUD study reported that unexpectedly high HIV incidence (9 infections 
per 100 person-years) in men who asked for PrEP and who were asked by 
clinician to defer starting the medication:
- HIV incidence was 3x expected based on epidemiologic trends
- People at higher risk of HIV infection were more likely to seek PrEP
services, stay in care, and be adherent = the motivation is already there
iPrEx study: Evidence that PrEP is a strong attractor for those entering into a 
“season of high exposure to HIV”
- Temporal variation in risk behavior
Provider Handout
 Quick consult
 To be formalized into the UVM Academic Detailing program
 Future Goals:
 Academic Detailing
 Family Medicine Grand Rounds
 eLearning module on LGBT health (to include PrEP) in Frymoyer
project for current and future UVM COM students
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